Immuno-oncology drug developer iTeos Therapeutics (NASDAQ:ITOS) on Monday said it has entered into an agreement to be acquired by Concentra Biosciences for $10.047 in cash per share plus a contingent value right (CVR).
The deal consists of one non-transferable CVR, which represents the